The one-ring open hydrolysis intermediates of the cardioprotective agent dexrazoxane (ICRF-187) do not inhibit the growth of Chinese hamster ovary cells or the catalytic activity of DNA topoisomerase II

Anti-Cancer Drugs

Volumn 9, Issue 5, 1998, Pages 465-471

  Hasinoff, Brian B ^a   Kuschak, Theodore I ^a   Fattman, Cheryl L ^b,c   Yalowich, Jack C ^b,c  

^a UNIVERSITY OF MANITOBA   (Canada)

^b UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

^c UNIVERSITY OF PITTSBURGH CANCER INSTITUTE   (United States)

Author keywords

Bisdioxopiperazine; CHO; Cytotoxicity; Dexrazoxane; Hydrolysis intermediates; ICRF 187; Topoisomerase II

Indexed keywords

DNA TOPOISOMERASE (ATP HYDROLYSING); DOXORUBICIN; RAZOXANE;

ANIMAL CELL; ARTICLE; CARDIOTOXICITY; CHO CELL; CONTROLLED STUDY; ENZYME INHIBITION; HEART PROTECTION; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HYDROLYSIS; NONHUMAN; PRIORITY JOURNAL;

ANIMALS; CARDIOVASCULAR AGENTS; CATALYSIS; CELL DIVISION; CHO CELLS; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; CRICETINAE; DNA TOPOISOMERASES, TYPE II; DNA, SUPERHELICAL; HYDROLYSIS; RAZOXANE;

EID: 0031868806     PISSN: 09594973     EISSN: None     Source Type: Journal    
DOI: 10.1097/00001813-199806000-00014     Document Type: Article

References (34)

1. Swain SM, Whaley FS, Gerber MC, et al. Cardioprotection with dexrazoxane for doxorubicin-containing therapy in advanced breast cancer. J Clin Oncol 1997; 15: 1318-32.
2. Swain SM, Whaley F, Gerber MC, Ewer MS, Bianchine JR, Gams RA. Delayed administration of dexrazoxane provides cardioprotection for patients with advanced breast cancer treated with doxorubicin-containing therapy. J Clin Oncol 1997; 15: 1333-40.
3. Speyer JL, Green MD, Zeleniuch-Jacquotte A, et al. ICRF-187 permits longer treatment with doxorubicin in women with breast cancer. J Clin Oncol 1992; 10: 117-27.
4. Hasinoff BB, Hellmann K, Herman EH, Ferrans VJ. Chemical, biological and clinical aspects of dexrazoxane and other bisdioxopiperazines. Curr Med Chem 1998; 5: 1-28.
5. Hasinoff BB. Pharmacodynamics of the hydrolysis-activation of the cardioprotective agent (+)-1,2-bis(3,5-dioxopiperazinyl-1-yl)propane. J Pharm Sci 1994; 83: 64-7.
6. Hasinoff BB. An HPLC and spectrophotometric study of the hydrolysis of ICRF-187 (dexrazoxane, (+)-1,2-bis(3,5-dioxopiperazinyl-1-yl)propane and its one-ring opened intermediates. Int J Pharm 1994; 107: 67-76.
7. Buss JL, Hasinoff BB. The one-ring open hydrolysis product intermediates of the cardioprotective agent ICRF-187 (dexrazoxane) displace iron from iron-anthracycline complexes. Agents Actions 1993; 40: 86-95.
8. Buss JL, Hasinoff BB. Ferrous ion strongly promotes the ring opening of the hydrolysis intermediates of the antioxidant doxonibicin cardioprotective agent ICRF-187 (dexrazoxane). Arch Biocbem Biophys 1995; 317: 121-7.
9. Buss JL, Hasinoff BB. Metal ion-promoted hydrolysis of the antioxidant cardioprotective agent dexrazoxane (ICRF-187) and its one-ring open hydrolysis products to its metal-chelating active form. J Inorg Biochem 1997; 68: 101-8.
10. Hasinoff BB. Enzymatic ring-opening reactions of the chiral cardioprotective agent (+) (S)-ICRF-187 and its (-) (R)-enantiomer ICRF-186 by dihydropyrimidine amidohydrolase. Drug Metab Disp 1993; 21: 883-8.
11. Hasinoff BB, Venkataram S, Singh M, Kuschak TI. Metabolism of the cardioprotective agents dexrazoxane (ICRF-187) and levrazoxane (ICRF-186) by the isolated hepatocyte. Xenobiotica 1994; 24: 977-87.
12. Hasinoff BB. Stereoselective hydrolysis of ICRF-187 (dexrazoxane) and ICRF-186 by dihydropyrimidine amidohydrolase. Chirality 1994; 6: 213-5.
13. Huang Z-X, May PM, Quinlan KM, Williams DR, Creighton AM. Metal binding by pharmaceuticals. Part 2. Interactions of Ca(II), Cu(II), Fe(II), Mg(II), Mn(II) and Zn(II) with the intracellular hydrolysis products of the antitumor agent ICRF-159 and its inactive homologue ICRF-192. Agents Actions 1982; 12: 536-42.
14. Hasinoff BB. NADPH-cytochrome-P450 reductase promotes hydroxyl radical production by the iron complex of ADR-925, the hydrolysis product of ICRF-187 (dexrazoxane). Free Rad Res 1995; 22: 319-25.
15. Creighton AM, Hellmann K, Whitecross S. Antitumour activity in a series of bisdiketopiperazines. Nature 1969; 22: 384-5.
16. Witiak DT, Wei Y. Dioxopiperazines: chemistry and biology. Prog Drug Res 1991; 35: 249-63.
17. Tanabe K, Ikegami Y, Ishida R, Andoh T. Inhibition of topoisomerase II by antitumor agents bis(2,6-dioxopiperazine) derivatives. Cancer Res 1991; 51: 4903-8.
18. Ishida R, Miki T, Narita T, et al. Inhibition of intracellular topoisomerase II by antitumor bis(2,6-dioxopiperazine) derivatives: mode of cell growth inhibition distinct from that of cleavable complex-forming type inhibitors. Cancer Res 1991; 51: 4909-16.
19. Hasinoff BB, Kuschak TI, Yalowich JC, Creighton AM. A QSAR study comparing the cytotoxicity and DNA topoisomerase II inhibitory effects of bisdiooxopiperazine analogs of ICRF-187 (dexrazoxane). Biochem Pharmacol 1995; 50: 953-8.
20. Hasinoff BB, Yalowich JC, Ling Y, Buss JL. The effect of dexrazoxane (ICRF-187) on doxorubicin- and daunorubicin-mediated growth inhibition of Chinese hamster ovary cells. Anti-Cancer Drugs 1996; 7: 558-67.
21. Corbett AH, Osheroff N. When good enzymes go bad: conversion of topoisomerase II to a cellular toxin by antineoplastic drugs. Chem Res Toxicol 1993; 6: 558-97.
22. Tewey KM, Rowe TC, Yang L, Halligan BD, Liu LF. Adriamycin-induced DNA damage mediated by mammalian DNA topoisomerase II. Science 1984; 226: 466-8.
23. Bodley A, Liu LF, Israel M, et al. DNA topoisomerase II-mediated interaction of doxorubicin and daunorubicin congeners with DNA. Cancer Res 1989; 49: 5969-78.
24. D'Arpa P, Liu LF. Topoisomerase-targeting antitumor drugs. Biochim Biophys Acta 1989; 989: 163-77.
25. Glisson BS, Ross WE. DNA topoisomerase II: a primer on the enzyme and its unique role as a multidrug target in cancer chemotherapy. Pharmacol Ther 1987; 32: 89-106.
26. Sehested M, Jensen PB, Sorensen BS, Holm B, Friche E, Demant EJF. Antagonistic effect of the cardioprotector (+)-1,2-bis(3,5-dioxopiperazinyl-1-yl)propane (ICRF-187) on DNA breaks and cytotoxicity induced by the topoisomerase II directed drugs daunorubicin and etoposide (VP-16). Biochem Pharmacol 1993; 46: 389-93.
27. Roca J, Ishida R, Berger JM, Andoh T, Wang JC. Antitumor bisdioxopiperazines inhibit yeast DNA topoisomerase II by trapping the enzyme in the form of a closed protein clamp. Proc Natl Acad Sci USA 1994; 91: 1781-5.
28. Hasinoff BB, Kuschak TI, Creighton AM, et al. Characterization of a Chinese hamster ovary cell line with acquired resistance to the bisdioxopiperazine dexrazoxane (ICRF-187) catalytic inhibitor of topoisomerase II. Biochem Pharmacol 1997; 53: 1843-53.
29. Marks DC, Belov L, Davey MW, Davey RD, Kidman AD. The MTT cell viability assay for cytotoxicity testing in multidrug-resistant human leukemic cells. Leuk Res 1992; 16: 1165-73
30. Sahai BM, Kaplan JG. A quantitative decatenation assay for type II topoisomerases. Anal Biochem 1986; 156: 364-79.
31. Fattman C, Allan WP, Hasinoff BB, Yalowich JC. Collateral sensitivity to the bisdioxopiperazine dexrazoxane (ICRF-187) in etoposide (VP-16) resistant human leukemia K562 cells. Biochem Pharmacol 1996; 52: 635-42.
32. Ritke MK, Roberts D, Allan WP, Raymond J, Bergoltz W, Yalowich JC. Altered stability of etoposide-induced topoisomerase II-DNA complexes in resistant human leukemia K562 cells. BrJ Cancer 1994; 69: 687-97.
33. Hasinoff BB, Kozlowska H, Creighton AM, Allan WP, Thampatty P, Yalowich JC. Mitindomide is a catalytic inhibitor of DNA topoisomerase II that acts at the bisdioxopiperazine binding site. Mol Pharmacol 1997; 52: 839-45.
34. Hellmann K, Field EO. Effect of ICRF 159 on the mammalian cell cycle: significance for its use in cancer chemotherapy. J Natl Cancer Inst 1970; 44: 539-43.